CD274 and non-small cell lung carcinoma: A total of 185 patients with NSCLC who were treated with anti-PD-1 Ab (pembrolizumab or nivolumab) or anti-PD-L1 Ab (atezolizumab) between February 2017 and February 2021 were included (Table 1).